JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Want to see JP:4552 full AI Analyst Report?
4552 Stock Chart & Stats
¥712.00
-¥21.00(-3.43%)
At close: 4:00 PM EST
¥712.00
-¥21.00(-3.43%)
Day’s Range― - ―
52-Week Range¥445.00 - ¥824.00
Previous CloseN/A
Volume326.50K
Average Volume (3M)578.69K
Market Cap
¥55.56B
Enterprise Value¥100.52B
Total Cash (Recent Filing)¥13.18B
Total Debt (Recent Filing)¥40.10B
Price to Earnings (P/E)25.1
Beta0.88
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)-45.01
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)1.48
Price to Sales (P/S)1.72
P/FCF Ratio-5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥564.00Price Target Upside-20.79% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)1.64
Revenue Forecast (FY)¥43.86B
Bulls Say, Bears Say
Bulls Say
Niche Specialty Pharma FocusJCR's focus on rare-disease biologics and advanced drug delivery creates structural barriers: long development cycles, specialized regulatory pathways, and high switching costs for clinicians. Its contract manufacturing capabilities diversify revenue and leverage factory scale over the medium term.
Recent Revenue Rebound And GrowthA durable top-line rebound indicates recovering product demand and commercial traction after disruption. Sustained revenue growth helps absorb fixed manufacturing costs, supports reinvestment in the pipeline, and improves the firm's ability to fund operations without relying solely on external capital.
Consistently Strong Gross ProfitStable gross profit suggests durable product economics and pricing power in specialized therapies. Strong unit margins provide a buffer against SG&A or R&D variability and support long-term profitability if operating expenses and cash conversion improve.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow undermines the firm's ability to self-fund R&D, capex, and working capital. Over a 2–6 month horizon this elevates refinancing and execution risk, increasing dependence on external financing and potentially constraining strategic initiatives.
Meaningfully Higher LeverageA jump in debt reduces financial flexibility and raises interest and covenant risk if cash generation reverts. Higher leverage magnifies downside on earnings volatility and may force prioritization of deleveraging over growth investments or pipeline funding.
Volatile Profitability HistoryLarge year-to-year swings in operating results indicate earnings instability, complicating long-term planning and making cash flows unpredictable. Persistent volatility weakens credit profiles, reduces ability to commit to multi-year R&D programs, and raises investor and payer scrutiny.
JCR Pharmaceuticals Co., Ltd. News
4552 FAQ
What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥445.00 and its highest was ¥824.00 in the past 12 months.
What is JCR Pharmaceuticals Co., Ltd.’s market cap?
JCR Pharmaceuticals Co., Ltd.’s market cap is ¥55.56B.
When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jul 29, 2026 which is in 44 days.
How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
JCR Pharmaceuticals Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥3.57 earnings per share for the quarter, beating the consensus estimate of -¥6.628 by ¥10.198.
Is JCR Pharmaceuticals Co., Ltd. overvalued?
According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Overvalued.
Does JCR Pharmaceuticals Co., Ltd. pay dividends?
JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥9.922 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
JCR Pharmaceuticals Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥3.57 in its last earnings report, beating expectations of -¥6.628. Following the earnings report the stock price went up 0.896%.
Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.
4552 Stock 12 Month Forecast
Average Price Target
¥564.00
▼(-20.79% Downside)
Technical Analysis
Kyowa Kirin Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---